[HTML][HTML] National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: IIb. The 2020 preemptive …
J Pidala, C Kitko, SJ Lee, P Carpenter… - … and cellular therapy, 2021 - Elsevier
Chronic graft-versus-host disease (GVHD) commonly occurs after allogeneic hematopoietic
cell transplantation (HCT) despite standard prophylactic immune suppression. Intensified
universal prophylaxis approaches are effective but risk possible overtreatment and may
interfere with the graft-versus-malignancy immune response. Here we summarize
conceptual and practical considerations regarding preemptive therapy of chronic GVHD,
namely interventions applied after HCT based on evidence that the risk of developing …
cell transplantation (HCT) despite standard prophylactic immune suppression. Intensified
universal prophylaxis approaches are effective but risk possible overtreatment and may
interfere with the graft-versus-malignancy immune response. Here we summarize
conceptual and practical considerations regarding preemptive therapy of chronic GVHD,
namely interventions applied after HCT based on evidence that the risk of developing …